Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, has today announced a commercial contract with UK based technology and innovation centre, the Centre for Process Innovation (CPI).
The project will focus on examining the potential of the Microsaic Mass Spectrometry (MS) offering as an online, deployable tool for the elucidation of biopharmaceutical or biologic structure during the manufacturing or bioprocessing workflow. Microsaic’s technology is a powerful point of use analysis tool which can be integrated into complex manufacturing workflows, which has the potential to be utilised in upstream cell media, or downstream biologic purification. A typical workflow could benefit from real-time data to drive production optimisation, ensure process control compliance, and reduce risk for the final product.
CPI brings together state of the art facilities and technical expertise to help companies overcome innovation challenges in the manufacture of biologics. CPI is the UK’s national technology and innovation centre for the process manufacturing industries. At the National Biologics Manufacturing Centre in Darlington, UK, CPI combines state of the art facilities and technical expertise to support the growth and development of the UK biologics industry and supply chain.
Glenn Tracey, Microsaic Systems plc CEO, commented “The UK is well positioned as one of the leading countries for process innovation, especially for high value biologics. It is fitting, therefore, that two high-technology businesses such as Microsaic and CPI, both based in the UK, should embark on such exciting knowledge-based work, paving the way for enabling technologies to meet the future quality and compliance needs in biopharma.”
